BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO by Hammitzsch, A, de Wit, J, Ridley, A, Al-Mossawi, M, Knapp, S, Bowness, P

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis. by Chen, L, Ridley, A, Hammitzsch, A, Al-Mossawi, M, Bunting, H, Georgiadis, D, Chan, A, Kollnberger, S, Bowness, P

Immune effector cells in SpA: What are the pathways? by Bowness, P, Ridley, A, Chen, L, Shi, H, Zaarour, N, Yager, N, Simone, D, Hammitzsch, A, Al-Mossawi, M

Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases by Hammitzsch, A, Chen, L, de Wit, J, Al-Mossawi, H, Ridley, A, Sekine, T, Simone, D, Doig, K, Skapenko, A, Bowness, P

miR-10b-5p is a novel Th17 regulator present in Th17 cells from Ankylosing Spondylitis by Chen, L, Al-Mossawi, M, Ridley, A, Sekine, T, Hammitzsch, A, de Wit, J, Shi, H, Penkava, F, Stolarska, M, Pulyakhina, I, Knight, J, Kim, T, Bowness, P

Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes by Hammitzsch, A, Ossadnik, A, Bachmann, Q, Merwald-Fraenk, H, Lorenz, G, Witt, M, Wiesent, F, Mühlhofer, H, Simone, D, Bowness, P, Heemann, U, Arbogast, M, Moog, P, Schmaderer, C

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. by Hammitzsch, A, Tallant, C, Fedorov, O, O'Mahony, A, Brennan, P, Hay, D, Martinez, F, Al-Mossawi, M, de Wit, J, Vecellio, M, Wells, C, Wordsworth, B, Müller, S, Knapp, S, Bowness, P

Unique trancriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis by Al-Mossawi, M, Chen, L, Fang, H, Ridley, A, de Wit, J, Yager, N, Hammitzsch, A, Pulyakhina, I, Fairfax, B, Simone, D, Yi, Y, Bandyopadhyay, S, Doig, K, Gundle, R, Kendrick, B, Powrie, F, Knight, J, Bowness, P